Orchid Pharma Ltd. - Research Center
524372 ORCHIDPHAR Group (T) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 296.24 | 339.53 | 217.45 | 227.57 | 238.69 |
| Operating profit | 30.27 | 45.37 | 11.89 | 39.71 | -37.06 |
| Interest | 17.06 | 11.24 | 20.77 | 26.92 | 1.87 |
| Gross profit | 21.98 | 38.24 | -3.99 | 15.00 | -26.22 |
| EPS (Rs) | -4.27 | -2.64 | 1.46 | -5.01 | -10.01 |
Half yearly
results in details
| Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 8.77 | 4.11 | 4.89 | 2.20 | 12.71 |
| Stock adjustment | -55.01 | 14.30 | -37.03 | -35.22 | 6.83 |
| Raw material | 225.13 | 180.06 | 156.74 | 125.39 | 111.48 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 32.31 | 29.98 | 30.22 | 36.40 | 40.34 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 63.54 | 69.81 | 55.62 | 61.29 | 117.10 |
| Provisions made | - | - | - | - | - |
| Depreciation | 39.39 | 46.85 | 40.17 | 59.58 | 62.84 |
| Taxation | - | - | - | - | - |
| Net profit / loss | -17.41 | -10.77 | 5.97 | -44.59 | -89.05 |
| Extra ordinary item | - | -2.16 | 50.13 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 40.82 | 40.82 | 40.82 | 88.96 | 88.96 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 10.22 | 13.36 | 5.47 | 17.45 | -15.53 |
| GPM (%) | 7.21 | 11.13 | -1.80 | 6.53 | -10.43 |
| NPM (%) | -5.71 | -3.14 | 2.68 | -19.41 | -35.42 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis